Specialized Intranasal Pain Relief Solutions

Publication ID: 24-11857520_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Intranasal Pain Relief Solutions,” Published Technical Disclosure No. 24-11857520_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857520_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,520.

Summary of the Inventive Concept

This inventive concept adapts the original therapeutic composition of intranasal lidocaine for specific, narrow markets or unique operational environments, providing targeted pain relief solutions for high-altitude environments, disaster relief, high-security needs, extreme weather conditions, and remote or isolated areas.

Background and Problem Solved

The original patent disclosed a preservative-free intranasal composition for treating various types of pain. However, this composition may not be suitable for specific, challenging environments or situations where standard pain relief solutions may not be effective or may pose risks. This inventive concept addresses these limitations by developing specialized variations of the original composition, tailored to meet the unique demands of these niche markets.

Detailed Description of the Inventive Concept

The new inventive concept comprises a series of specialized intranasal pain relief solutions, each designed to address the specific challenges of a particular environment or situation. For high-altitude environments, the composition is formulated to mitigate the effects of altitude-induced hypoxia on pain perception. In disaster relief scenarios, the system includes a portable, battery-powered nasal spray pump device and a cooling device to maintain the composition at a stable temperature. For high-security environments, the composition is formulated to minimize the risk of diversion or misuse. In extreme weather conditions, the portable, handheld nasal spray device features a waterproof and shock-resistant housing. Finally, for remote or isolated areas, the composition is designed to be stable at ambient temperatures and humidity levels.

Novelty and Inventive Step

The new inventive concept introduces novel and non-obvious variations of the original composition, specifically tailored to address the unique challenges of specialized markets and environments. These variations include the formulation of the composition to mitigate altitude-induced hypoxia, the integration of a cooling device in the disaster relief system, and the design of a waterproof and shock-resistant housing for the handheld device in extreme weather conditions.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the development of specialized nasal spray devices for use in other challenging environments, such as space exploration or underwater operations. Additionally, the composition could be adapted for use in veterinary medicine, providing targeted pain relief solutions for animals in various environments.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in various industries, including pharmaceuticals, medical devices, disaster relief, and high-security services. The specialized pain relief solutions could be marketed to organizations operating in challenging environments, such as search and rescue teams, high-altitude research stations, or military units. The potential market for these solutions is substantial, with opportunities for partnerships, licensing agreements, and direct sales.

CPC Classifications

SectionClassGroup
A A61 A61K31/167
A A61 A61K9/0043
A A61 A61M11/00
A A61 A61M2210/0618

Field of Art

Pharmaceutical formulations, specifically intranasal drug delivery systems for pain management, involving expertise in pharmacology, drug formulation, medical device design, and spray delivery technologies

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degree (MS/PhD) in pharmaceutical sciences or biomedical engineering, with practical experience in drug delivery system design, nasal spray technology, and understanding of pain management pharmacotherapeutics

Obviousness Rationale

A PHOSITA would recognize that the specialized intranasal pain relief solutions represent predictable variations of the source patent's core technology, applying standard engineering design principles and known adaptation strategies to address specific environmental challenges while maintaining the fundamental therapeutic mechanism of preservative-free intranasal lidocaine delivery.

Obvious Combinations & Variations

Source Patent Element
Preservative-free intranasal lidocaine composition for pain management
PTD Variation
Formulation adapted for high-altitude environments to mitigate altitude-induced hypoxia effects
Obviousness Reasoning
Known pharmacological techniques for modifying drug delivery based on physiological conditions, representing a predictable solution using standard pharmaceutical engineering approaches
Source Patent Element
Multi-dose mechanical nasal spray pump device
PTD Variation
Waterproof and shock-resistant housing for extreme weather conditions
Obviousness Reasoning
Routine mechanical engineering design modification to extend device functionality, using standard protective enclosure techniques known in medical device development
Source Patent Element
Intranasal lidocaine composition for pain treatment
PTD Variation
Disaster relief system with portable battery-powered spray and temperature-controlled cooling device
Obviousness Reasoning
Combination of known medical device technologies representing a predictable integration of existing technological solutions for improved drug delivery reliability
Source Patent Element
Nasal spray formulation with sodium channel blocker
PTD Variation
Composition formulated to minimize diversion risk in high-security environments
Obviousness Reasoning
Applying standard pharmaceutical security protocols through predictable chemical or physical modifications to prevent unauthorized use
Source Patent Element
Unit-dose intranasal spray with 5-20 mg lidocaine
PTD Variation
Composition stable at ambient temperatures for use in remote or isolated areas
Obviousness Reasoning
Routine pharmaceutical formulation optimization using known stabilization techniques to extend drug shelf life and environmental adaptability
35 U.S.C. § 103 Summary: Based on US Patent 11857520's disclosure of preservative-free intranasal lidocaine compositions, the present published technical disclosure demonstrates that the claimed variations represent obvious extensions of the prior art, employing standard pharmaceutical engineering techniques to adapt the core therapeutic technology to specialized environmental contexts, thereby rendering subsequent claims of novelty invalid under 35 U.S.C. ยง 103.

Original Patent Information

Patent NumberUS 11,857,520
TitleTherapeutic composition of intranasal lidocaine
Assignee(s)Nortic Holdings Inc.